Literature DB >> 2911527

Cancer survivors at work: job problems and illegal discrimination.

B Hoffman.   

Abstract

Approximately 25% of the five million people in the United States with a cancer history experience disparate treatment in employment solely because of their medical histories. Many employers do not realize that more than half of the people diagnosed with cancer in 1988 in the United States will overcome their illness, that cancer is not contagious, and that cancer survivors have relatively the same productivity rates as other workers. Decisions to deny employment opportunities to cancer survivors that are based on misconceptions about cancer instead of the individual's ability to perform the job may violate the survivor's legal rights. Discrimination against individuals with a history of cancer, who are qualified for jobs, violates most federal and state laws that prohibit employment discrimination based on actual or perceived disabilities. Health professionals, as well as survivors themselves, must take action on three fronts to combat cancer-based discrimination: public and professional education, individual and group advocacy, and appropriate use of legal remedies.

Entities:  

Mesh:

Year:  1989        PMID: 2911527

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  4 in total

1.  The "Big C"-stigma, cancer, and workplace discrimination.

Authors:  Mary Stergiou-Kita; Cheryl Pritlove; Bonnie Kirsh
Journal:  J Cancer Surviv       Date:  2016-05-12       Impact factor: 4.442

2.  Measurement of the quality of life in cancer survivors.

Authors:  B R Ferrell; K H Dow; M Grant
Journal:  Qual Life Res       Date:  1995-12       Impact factor: 4.147

3.  Factors influencing changes in employment among women with newly diagnosed breast cancer.

Authors:  Michael J Hassett; A James O'Malley; Nancy L Keating
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

4.  Adjuvant chemotherapy does not affect employment in patients with early-stage breast cancer.

Authors:  P W Bushunow; Y Sun; R F Raubertas; S Rosenthal
Journal:  J Gen Intern Med       Date:  1995-02       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.